{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:17:47Z","timestamp":1782544667859,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jns.2019.116601","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T11:13:21Z","timestamp":1574853201000},"page":"116601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience"],"prefix":"10.1016","volume":"409","author":[{"given":"Richard Shek-kwan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi Ki Kate","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Tung Colin","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.Y. William","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Hin Ian","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie Olivia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2019.116601_bb0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2019.116601_bb0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2019.116601_bb0015","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2019.116601_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2019.116601_bb0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2019.116601_bb0030","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2019.116601_bb0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eplepsyres.2016.08.032","article-title":"Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study","volume":"127","author":"Hong","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2019.116601_bb0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yebeh.2009.07.043","article-title":"Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany","volume":"16","author":"Wehner","year":"2009","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2019.116601_bb0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clineuro.2018.06.022","article-title":"Lacosamide efficacy and tolerability in clinical practice - post marketing analysis from a single dedicated epilepsy center","volume":"171","author":"Baker","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2019.116601_bb0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yebeh.2018.04.020","article-title":"Efficacy and tolerability of treatment with lacosamide: postmarketing experience from the Middle East region","volume":"84","author":"Arabi","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2019.116601_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ebcr.2016.09.006","article-title":"Unmasking of myoclonus by lacosamide in generalized epilepsy","volume":"7","author":"Birnbaum","year":"2017","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.jns.2019.116601_bb0060","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.yebeh.2011.01.022","article-title":"Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine","volume":"20","author":"Belcastro","year":"2011","journal-title":"Epilepsy Behav."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19323664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19323664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:48:09Z","timestamp":1758383289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X19323664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":12,"alternative-id":["S0022510X19323664"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2019.116601","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2019.116601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116601"}}